Arrowhead and Horizon enter up to $700m deal to develop RNAi drug
Arrowhead will get an upfront payment of $40m from Horizon in exchange for a global licence to the siRNA therapeutic.
Diseases
Sanofi’s Aubagio obtains EC approval for paediatric multiple sclerosis
The EC granted approval based on positive results from the Phase III TERIKIDS trial of...
Eisai and BMS partner to develop antibody drug conjugate for cancer
Eisai will get $650m from BMS and is also eligible for nearly $2.45bn in potential...
Debiopharm and Ubix join forces to develop new anti-cancer modality
The companies are combining their proprietary technologies to develop Antibody Degraducer Conjugates.
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
Novartis prostate cancer drug gets FDA breakthrough designation
The FDA breakthrough designation is based on positive results from the Phase III VISION study of ¹⁷⁷Lu-PSMA-617.
Umoja Biopharma raises $210m to develop cancer treatments
The funds will also be used to set up internal manufacturing capabilities to clinically develop pipeline programmes.
HiFiBiO raises series D funds to advance immuno-oncology candidates
HiFiBiO Therapeutics plans to accelerate two immuno-oncology programmes and to validate its Drug Intelligent Science platform in clinical trials.
GSK and iTeos partner to develop antibody for cancer treatment
iTeos will receive an upfront payment of $625m and is eligible to get up to $1.45bn in potential milestone payments.
Exercise should be first line of defence against elevated blood pressure
Healthcare experts have recommended exercise as a first-line treatment for mild to moderate-risk blood pressure and cholesterol.
Vertex’s Trikafta gets FDA approval to treat cystic fibrosis in children
Trikafta received FDA approval for cystic fibrosis patients aged six to 11, having previously received the FDA nod for treating patients aged 12 and above.
